JIC
MXCT icon

Johnson Investment Counsel’s MaxCyte MXCT Stock Holding History

Johnson Investment Counsel’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,815
Closed -$33.7K – 725
2023
Q3 		$33.7K Buy
+10,815
New +$43.5K ﹤0.01% 670

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Johnson Investment Counsel's MXCT Position: Q4 2023 in Review

Johnson Investment Counsel sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 10,815 shares — an estimated $33.7K sold.

Johnson Investment Counsel first reported a position in MXCT in Q3 2023 and held it in 1 quarter. The position peaked at $33.7K in Q3 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

  • Johnson Investment Counsel reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
  • Johnson Investment Counsel sold 10,815 MaxCyte shares in Q4 2023, an estimated $33.7K.
  • Johnson Investment Counsel first reported a position in MaxCyte in Q3 2023 and held it in 1 quarter.
  • Johnson Investment Counsel's MaxCyte position peaked at $33.7K in Q3 2023.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Johnson Investment Counsel's 13F filing for Q4 2023, filed 7 Feb 2024.